ArticleOphthalmology and therapy2025
The Effect of Repeated Low-Level Red Light Versus 0.01% Atropine Treatment on Axial Length and Choroidal Parameters in Children with Myopia.
Article in Ophthalmology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A natural experiment in school lighting: observational evidence linking far-red light exposure to slower myopia progression in Chinese Uyghur schoolchildren.BMC public health · 2026Observational
- Choroidal Structural and Vascular Changes During Myopia Progression and in Response to Myopia Control Interventions: A Systematic Review.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionThis research was designed to compare the effectiveness of repeated low-level red light (RLRL) and 0.01% atropine on axial length (AL), spherical equivalent refraction (SER), and choroidal parameters in children with myopia.
methodsWe conducted a prospective, randomized, and single-blind controlled trial. Ninety-one children aged 6-12 years old were selected, with cycloplegic SER ≥ - 5.00 D and ≤ - 0.75 D. Participants were randomly assigned to the RLRL group and 0.01% atropine group. The primary outcomes included changes in AL, SER, and choroidal parameters after a duration of 6 months. Choroidal parameters specifically including the foveal, parafoveal, and perifoveal choroidal thickness (ChT) and the foveal, parafoveal, and perifoveal choroidal vessel volume (CVV).
resultsAt 6-month follow-up, the AL and SER changes were - 0.09 mm (- 0.18, 0.01) compared to 0.13 mm (0.05, 0.24) (p < 0.001) and 0.25 D (0, 0.50) compared to - 0.25 D (- 0.53, 0) (p < 0.001) in the RLRL and 0.01% atropine groups. The foveal, parafoveal and perifoveal ChT changes were 36.38 µm (14.05, 65.39), 31.04 µm (4.09, 59.35), and 28.48 µm (5.35, 55.15), compared to 0.94 µm (- 9.20, 9.36), 3.52 µm (- 10.24, 14.45), and 6.14 µm (- 5.21, 15.69) (all p < 0.001) in the RLRL and 0.01% atropine groups. The foveal, parafoveal, and perifoveal CVV changes were 0.01 μm
conclusionsAfter 6 months of treatment, RLRL was more effective than 0.01% atropine in controlling axial elongation and myopic progression among children with myopia. The foveal, parafoveal, and perifoveal ChT and foveal, parafoveal, and perifoveal CVV changes in the RLRL group were significantly higher than those in the 0.01% atropine group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.